3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
30
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Neoplasms
6
Colorectal Neoplasms
6
Adenocarcinoma
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Solid Cancer
1
Interventions
pembrolizumab
3
entrectinib
2
zanidatamab
1
trastuzumab deruxtecan
1
spartalizumab
1
neratinib
1
larotrectinib
1
cevimeline
1
apalutamide
1
alectinib
1
Tablets
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Gonadotropin-Releasing Hormone
1
Fentanyl
1
EBC-46
1
Drug Therapy
1
Docetaxel
1
Combined Modality Therapy
1
Carboplatin
1
Biological Therapy
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Salivary Gland Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled